Alembic Pharma gets USFDA VAI classification for Panelav facility

Published On 2020-05-05 06:55 GMT   |   Update On 2021-08-19 11:09 GMT

Gujrat: Alembic Pharma has announced that the US Food and Drug Administration (USFDA) has classified the Company's General Oral Solid Formulation Facility located at Panelav as Voluntary Action Indicated (VAI). Inspection at the said Facility was conducted by USFDA from 9th March 2020 to 13th March 2020.VAI means USFDA accepted the Company's response to its observations.Alembic...

Login or Register to read the full article

Gujrat: Alembic Pharma has announced that the US Food and Drug Administration (USFDA) has classified the Company's General Oral Solid Formulation Facility located at Panelav as Voluntary Action Indicated (VAI).

Inspection at the said Facility was conducted by USFDA from 9th March 2020 to 13th March 2020.

VAI means USFDA accepted the Company's response to its observations.

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company headquartered in Gujarat.

Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.

Read also: Alembic Pharma Q4 Results: Net Profit Up 81% To Rs 225 Crore

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News